Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 834231, 10 pages
http://dx.doi.org/10.1093/ecam/nep175
Original Article

The Herb Medicine Formula “Chong Lou Fu Fang” Increases the Cytotoxicity of Chemotherapeutic Agents and Down-Regulates the Expression of Chemotherapeutic Agent Resistance-Related Genes in Human Gastric Cancer Cells In Vitro

1Department of Oncology, Nanjing Drum Tower Hospital, Nanjing University of Traditional Chinese Medicine, Zhongshan Road 321, Nanjing 210008, China
2Clinical Oncology Laboratory, Changzhou Tumor Hospital Affiliated to Medical School of Suzhou University, Huaide Road 44, Changzhou 213002, China
3Department of Internal Medicine, Traditional Chinese Medicine Hospital of Changzhou, Heping Road 156, Changzhou 213002, China

Received 31 May 2009; Accepted 2 October 2009

Copyright © 2011 Yongping Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. K. Leung, M.-S. Wu, Y. Kakugawa et al., “Screening for gastric cancer in Asia: current evidence and practice,” The Lancet Oncology, vol. 9, no. 3, pp. 279–287, 2008. View at Publisher · View at Google Scholar · View at PubMed
  2. F. Kamangar, G. M. Dores, and W. F. Anderson, “Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world,” Journal of Clinical Oncology, vol. 24, no. 14, pp. 2137–2150, 2006. View at Publisher · View at Google Scholar · View at PubMed
  3. S. A. Hundahl, J. L. Phillips, and H. R. Menck, “The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth Edition American Joint Committee on Cancer staging, proximal disease, and the 'different disease' hypothesis,” Cancer, vol. 88, no. 4, pp. 921–932, 2000. View at Publisher · View at Google Scholar
  4. J. A. Ajani, “Evolving chemotherapy for advanced gastric cancer,” Oncologist, vol. 10, no. 3, pp. 49–58, 2005. View at Publisher · View at Google Scholar · View at PubMed
  5. M. A. Richardson, T. Sanders, J. L. Palmer, A. Greisinger, and S. E. Singletary, “Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology,” Journal of Clinical Oncology, vol. 18, no. 13, pp. 2505–2514, 2000. View at Google Scholar
  6. H. Boon, M. Stewart, M. A. Kennard et al., “Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions,” Journal of Clinical Oncology, vol. 18, no. 13, pp. 2515–2521, 2000. View at Google Scholar
  7. A. Sparber and J. C. Wootton, “Surveys of complementary and alternative medicine: part II. Use of alternative and complementary cancer therapies,” Journal of Alternative and Complementary Medicine, vol. 7, no. 3, pp. 281–287, 2001. View at Google Scholar
  8. Y. Cui, X.-O. Shu, Y. Gao et al., “Use of complementary and alternative medicine by Chinese women with breast cancer,” Breast Cancer Research and Treatment, vol. 85, no. 3, pp. 263–270, 2004. View at Publisher · View at Google Scholar · View at PubMed
  9. Y. X. Wang and H. F. Li, “Progress of the anti-tumor study of Rhizoma Paridis,” Chinese Traditional and Herbal Drugs, vol. 36, pp. 628–630, 2005 (Chinese). View at Google Scholar
  10. J. Sun, B.-R. Liu, W.-J. Hu, L.-X. Yu, and X.-P. Qian, “In vitro anticancer activity of aqueous extracts and ethanol extracts of fifteen traditional Chinese medicines on human digestive tumor cell lines,” Phytotherapy Research, vol. 21, no. 11, pp. 1102–1104, 2007. View at Publisher · View at Google Scholar · View at PubMed
  11. Z.-X. Cheng, B.-R. Liu, X.-P. Qian et al., “Proteomic analysis of anti-tumor effects by Rhizoma Paridis total saponin treatment in HepG2 cells,” Journal of Ethnopharmacology, vol. 120, no. 2, pp. 129–137, 2008. View at Publisher · View at Google Scholar · View at PubMed
  12. C.-Y. Li, H.-X. Xu, Q.-B. Han, and T.-S. Wu, “Quality assessment of Radix Codonopsis by quantitative nuclear magnetic resonance,” Journal of Chromatography A, vol. 1216, no. 11, pp. 2124–2129, 2009. View at Publisher · View at Google Scholar · View at PubMed
  13. T.-C. Chou and P. Talalay, “Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors,” Advances in Enzyme Regulation, vol. 22, pp. 27–55, 1984. View at Google Scholar
  14. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at PubMed
  15. D. M. Eisenberg, R. B. Davis, S. L. Ettner et al., “Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey,” Journal of the American Medical Association, vol. 280, no. 18, pp. 1569–1575, 1998. View at Google Scholar
  16. J. Li, G.-Z. Sun, H.-S. Lin et al., “The herb medicine formula “Yang Wei Kang Liu” improves the survival of late stage gastric cancer patients and induces the apoptosis of human gastric cancer cell line through Fas/Fas ligand and Bax/Bcl-2 pathways,” International Immunopharmacology, vol. 8, no. 9, pp. 1196–1206, 2008. View at Publisher · View at Google Scholar · View at PubMed
  17. A. K. Garg, T. A. Buchholz, and B. B. Aggarwal, “Chemosensitization and radiosensitization of tumors by plant polyphenols,” Antioxidants and Redox Signaling, vol. 7, no. 11-12, pp. 1630–1647, 2005. View at Publisher · View at Google Scholar · View at PubMed
  18. A. D. Wagner, W. Grothe, J. Haerting, G. Kleber, A. Grothey, and W. E. Fleig, “Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data,” Journal of Clinical Oncology, vol. 24, no. 18, pp. 2903–2909, 2006. View at Publisher · View at Google Scholar · View at PubMed
  19. S.-E. Al-Batran, J. T. Hartmann, S. Probst et al., “Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie,” Journal of Clinical Oncology, vol. 26, no. 9, pp. 1435–1442, 2008. View at Publisher · View at Google Scholar · View at PubMed
  20. E. Van Cutsem, V. M. Moiseyenko, S. Tjulandin et al., “Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V25 study group,” Journal of Clinical Oncology, vol. 24, no. 31, pp. 4991–4997, 2006. View at Publisher · View at Google Scholar · View at PubMed
  21. R. Matuo, F. G. Sousa, A. E. Escargueil et al., “5-fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line,” Journal of Applied Toxicology, vol. 29, no. 4, pp. 308–316, 2009. View at Publisher · View at Google Scholar · View at PubMed
  22. S. Faivre, D. Chan, R. Salinas, B. Woynarowska, and J. M. Woynarowski, “DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells,” Biochemical Pharmacology, vol. 66, no. 2, pp. 225–237, 2003. View at Publisher · View at Google Scholar
  23. N. Matsuhashi, M. Saio, A. Matsuo, Y. Sugiyama, and S. Saji, “Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines,” International Journal of Oncology, vol. 26, no. 6, pp. 1563–1567, 2005. View at Google Scholar
  24. R. Schimming, K. A. Mason, N. Hunter, M. Weil, K. Kishi, and L. Milas, “Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel,” Cancer Chemotherapy and Pharmacology, vol. 43, no. 2, pp. 165–172, 1999. View at Publisher · View at Google Scholar
  25. K.-H. Yeh, C.-T. Shun, C.-L. Chen et al., “High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy,” Cancer, vol. 82, no. 9, pp. 1626–1631, 1998. View at Publisher · View at Google Scholar
  26. H. Kuramochil, K. Tanaka, D. Oh et al., “Thymidylate synthase polymorphisms and mRNA expression are independent chemotherapy predictive markers in esophageal adenocarcinoma patients,” International Journal of Oncology, vol. 32, no. 1, pp. 201–208, 2008. View at Google Scholar
  27. E. Reed, “Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy,” Cancer Treatment Reviews, vol. 24, no. 5, pp. 331–344, 1998. View at Google Scholar
  28. I. U. De Silva, P. J. McHugh, P. H. Clingen, and J. A. Hartley, “Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells,” Molecular and Cellular Biology, vol. 20, no. 21, pp. 7980–7990, 2000. View at Publisher · View at Google Scholar
  29. J. H. J. Hoeijmakers, “Genome maintenance mechanisms for preventing cancer,” Nature, vol. 411, no. 6835, pp. 366–374, 2001. View at Publisher · View at Google Scholar · View at PubMed
  30. R. Metzger, C. G. Leichman, K. D. Danenberg et al., “ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy,” Journal of Clinical Oncology, vol. 16, no. 1, pp. 309–316, 1998. View at Google Scholar
  31. R. Rosell, F. Cecere, M. Santarpia, N. Reguart, and M. Taron, “Predicting the outcome of chemotherapy for lung cancer,” Current Opinion in Pharmacology, vol. 6, no. 4, pp. 323–331, 2006. View at Publisher · View at Google Scholar · View at PubMed
  32. C. Sarries, E. B. Haura, B. Roig et al., “Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer,” Pharmacogenomics, vol. 3, no. 6, pp. 763–780, 2002. View at Publisher · View at Google Scholar · View at PubMed
  33. P. Sève and C. Dumontet, “Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?” The Lancet Oncology, vol. 9, no. 2, pp. 168–175, 2008. View at Publisher · View at Google Scholar · View at PubMed
  34. L. Pusztai, “Markers predicting clinical benefit in breast cancer from microtubule-targeting agents,” Annals of Oncology, vol. 18, pp. xii15–xii20, 2007. View at Publisher · View at Google Scholar · View at PubMed
  35. R. Rouzier, R. Rajan, P. Wagner et al., “Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 23, pp. 8315–8320, 2005. View at Publisher · View at Google Scholar · View at PubMed